Immunic, Inc. (IMUX) stock
IMUXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.33+0.10 (+1.38%)
Close on Nov 17, 2026Market cap $100.01MP/E –Yield 0.00%
Immunic operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Immunic's operating cash flow for the twelve months ending Jun 30, 2026 was -$87.72M. For fiscal 2025 it was -$85.81M. The highest annual figure on record is -$9.24M in fiscal 2012.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$85.81M | – |
| FY2024 | Dec 31, 2024 | -$84.77M | – |
| FY2023 | Dec 31, 2023 | -$70.83M | – |
| FY2022 | Dec 31, 2022 | -$65.14M | – |
| FY2021 | Dec 31, 2021 | -$83.23M | – |
| FY2020 | Dec 31, 2020 | -$46.12M | – |
| FY2019 | Dec 31, 2019 | -$28.55M | – |
| FY2018 | Dec 31, 2018 | -$9.74M | – |
| FY2017 | Dec 31, 2017 | -$40.40M | – |
| FY2016 | Dec 31, 2016 | -$35.77M | – |
| FY2015 | Dec 31, 2015 | -$49.95M | – |
| FY2014 | Dec 31, 2014 | -$40.83M | – |
| FY2013 | Dec 31, 2013 | -$28.65M | – |
| FY2012 | Dec 31, 2012 | -$9.24M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$31.00M | – |
| Q1 FY2026 | Mar 31, 2026 | -$17.30M | – |
| Q4 FY2025 | Dec 31, 2025 | -$19.28M | – |
| Q3 FY2025 | Sep 30, 2025 | -$20.14M | – |
| Q2 FY2025 | Jun 30, 2025 | -$24.61M | – |
| Q1 FY2025 | Mar 31, 2025 | -$21.78M | – |
| Q4 FY2024 | Dec 31, 2024 | -$22.96M | – |
| Q3 FY2024 | Sep 30, 2024 | -$20.80M | – |
| Q2 FY2024 | Jun 30, 2024 | -$17.04M | – |
| Q1 FY2024 | Mar 31, 2024 | -$23.97M | – |
| Q4 FY2023 | Dec 31, 2023 | -$14.03M | – |
| Q3 FY2023 | Sep 30, 2023 | -$17.31M | – |
| Q2 FY2023 | Jun 30, 2023 | -$19.98M | – |
| Q1 FY2023 | Mar 31, 2023 | -$19.51M | – |
| Q4 FY2022 | Dec 31, 2022 | -$15.10M | – |
| Q3 FY2022 | Sep 30, 2022 | -$13.60M | – |
| Q2 FY2022 | Jun 30, 2022 | -$15.76M | – |
| Q1 FY2022 | Mar 31, 2022 | -$20.68M | – |
| Q4 FY2021 | Dec 31, 2021 | -$23.68M | – |
| Q3 FY2021 | Sep 30, 2021 | -$17.60M | – |
| Q2 FY2021 | Jun 30, 2021 | -$29.01M | – |
| Q1 FY2021 | Mar 31, 2021 | -$12.95M | – |
| Q4 FY2020 | Dec 31, 2020 | -$13.96M | – |
| Q3 FY2020 | Sep 30, 2020 | -$11.91M | – |
| Q2 FY2020 | Jun 30, 2020 | -$9.23M | – |
| Q1 FY2020 | Mar 31, 2020 | -$11.03M | – |
| Q4 FY2019 | Dec 31, 2019 | -$6.27M | – |
| Q3 FY2019 | Sep 30, 2019 | -$5.98M | – |
| Q2 FY2019 | Jun 30, 2019 | -$10.99M | -223.9% |
| Q1 FY2019 | Mar 31, 2019 | -$5.32M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.45M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.09M | – |
| Q2 FY2018 | Jun 30, 2018 | $8.87M | – |
| Q1 FY2018 | Mar 31, 2018 | -$13.07M | – |
| Q4 FY2017 | Dec 31, 2017 | -$9.92M | – |
| Q3 FY2017 | Sep 30, 2017 | -$9.42M | – |
| Q2 FY2017 | Jun 30, 2017 | -$10.15M | – |
| Q1 FY2017 | Mar 31, 2017 | -$10.91M | – |
| Q4 FY2016 | Dec 31, 2016 | -$9.10M | – |
| Q3 FY2016 | Sep 30, 2016 | -$7.89M | – |
See a number that looks wrong?